NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University
21 déc. 2023 08h30 HE
|
NightHawk Biosciences
Next phase of multi-million-dollar project to include scaling up cGMP manufacturing for phase 1 trial targeting infectious disease CDMO services attracting considerable interest as...
NightHawk Biosciences Announces Major Milestone with Completion of Manufacturing Run for a Premier U.S.-Based Biopharmaceutical Company
18 déc. 2023 08h30 HE
|
NightHawk Biosciences
Manufacturing run at Scorpius’ state-of-the-art San Antonio microbial facility sets the stage for commercial manufacturing Advances multi-million dollar biomanufacturing contract awarded earlier this...
NightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core Assets
12 déc. 2023 08h30 HE
|
NightHawk Biosciences
Over $20 million in signed manufacturing contracts which includepremier biotech/pharma companies and research institutes Elusys divestiture and R&D cuts expected to eliminate over $40 million...
NightHawk Biosciences Provides Q3 2023 Business Update
20 nov. 2023 16h05 HE
|
NightHawk Biosciences
DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing,...
NightHawk Biosciences Provides Q2 2023 Business Update
14 août 2023 16h05 HE
|
NightHawk Biosciences
DURHAM, N.C., Aug. 14, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing,...
NightHawk Biosciences Provides Q1 2023 Business Update
15 mai 2023 16h05 HE
|
NightHawk Biosciences
DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing,...
NightHawk Biosciences Provides 2022 Year End Business Update
31 mars 2023 16h05 HE
|
NightHawk Biosciences
DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate...
NightHawk Biosciences Provides Third Quarter 2022 Business Update
14 nov. 2022 16h01 HE
|
NightHawk Biosciences
DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate...
Nighthawk Biosciences’ Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility
21 oct. 2022 08h00 HE
|
NightHawk Biosciences
DURHAM, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate...
NightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) Laboratory
23 août 2022 07h30 HE
|
NightHawk Biosciences
DURHAM, N.C., Aug. 23, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate...